First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors
利维莫尼普利单抗(一种靶向 GARP:TGF-β1 复合物的抗体)作为单药疗法以及与抗 PD-1 抗体布迪加利单抗联合疗法治疗晚期实体瘤患者的首次人体 1 期剂量递增试验结果
期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2024.1376551
Shimizu, Toshio; Powderly, John; Abdul Razak, Albiruni; LoRusso, Patricia; Miller, Kathy D; Kao, Steven; Kongpachith, Sarah; Tribouley, Catherine; Graham, Michelle; Stoll, Brian; Patel, Maulik; Sahtout, Mohammad; Blaney, Martha; Leibman, Rachel; Golan, Talia; Tolcher, Anthony